Sentinel Lymph Node Clinical Trial
Official title:
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Initially Node Positive Breast Cancer Patients, Could it Omit Axillary Dissection ?
The aim of this study is to determine the accuracy and safety of SLNB after neoadjuvant chemotherapy.
Breast cancer is the most common cancer among women. The morbidity and mortality of breast cancer are much higher than those observed with other female cancers . The incidence of breast cancer increases with age. Approximately 1.7 million new cases are estimated to occur worldwide, and mortality is increasing in developing countries, primarily because the disease is not diagnosed until it is in an advanced stage Neoadjuvant chemotherapy (NACT) is considered the standard of care for the anagement of locally advanced breast cancer and although this treatment has historically been reserved for those with inoperable breast cancer now is increasingly being used for women with earlier stage disease. . Encouraging results obtained with neoadjuvant chemotherapy in have resulted in clinicians using preoperative chemotherapy for patients with smaller tumors. Neoadjuvant chemotherapy (NACT) could reduce surgical morbidity of the breast and axilla. By down staging of the tumor, NACT can convert patients who are candidates for mastectomy to breast-conserving surgery (BCS) candidates . Furthermore, it has potential to reduce excision volumes in patients with large tumors who are already candidates for BCS. Another surgical advantage is down staging of the axilla so that axillary lymph node dissection can be avoided . In the treatment of breast cancer, sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) as the staging procedure for patients with clinically node-negative disease. It provides accurate assessment of histological nodal status, guides additional therapies and is associated with less morbidity than ALND. Historically, patients who were clinically node-negative would undergo SLNB, whereas patients who were node-positive underwent ALND. SLNB in the neoadjuvant setting has become a topic of debate. Unfortunately, the reliability of SLNB after NAC remains questionable. Chemotherapy causes fibrosis, fat necrosis and granulation tissue formation, which alters lymphatic drainage patterns. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05437380 -
Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC
|
N/A | |
Active, not recruiting |
NCT04303715 -
No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography
|
N/A | |
Completed |
NCT05498051 -
Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.
|
N/A | |
Active, not recruiting |
NCT06169787 -
Sentinel Lymph Nodes Biopsy in Cervical Cancer
|
||
Completed |
NCT03294330 -
SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04930692 -
A Prospective Single-center Cohort Study "Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients"
|
N/A | |
Recruiting |
NCT03749707 -
HPV in Sentinel Lymph Nodes
|
N/A | |
Completed |
NCT03899441 -
Multimedia Aid Gynecologic Counseling and Consent
|
N/A | |
Recruiting |
NCT04826211 -
Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI
|
N/A | |
Recruiting |
NCT04664582 -
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
|
N/A | |
Withdrawn |
NCT04487912 -
Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer
|
Phase 4 | |
Completed |
NCT03563781 -
SEntine Lymph Node in earLY Ovarian Cancer (SELLY)
|
N/A | |
Recruiting |
NCT05623280 -
Artificial Intelligence Analysis of Fluorescence Image to Intraoperatively Detect Metastatic Sentinel Lymph Node.
|
||
Active, not recruiting |
NCT05359783 -
Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04568941 -
Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer
|
N/A | |
Completed |
NCT03606616 -
Prospective Feasibility Study Applying the ACOSOG Z0011 Criteria to Chinese Patients
|
||
Recruiting |
NCT02982148 -
Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients
|
Phase 4 | |
Recruiting |
NCT06161428 -
Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer
|
||
Completed |
NCT03900104 -
Cervical and Endometrial Injection for Sentinel Lymph Node Detection in Endometrial Cancer
|
N/A | |
Recruiting |
NCT04671511 -
Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer
|
N/A |